Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Shares Outstanding (Diluted Average) (2019 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $280.2 million as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 38.92% year-over-year to $280.2 million; the TTM value through Dec 2025 reached $280.2 million, up 38.92%, while the annual FY2025 figure was $280.2 million, 38.92% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $280.2 million in Q4 2025 for Sangamo Therapeutics, down from $304.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $304.3 million in Q3 2025 and bottomed at $143.1 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $186.1 million, with a median of $174.4 million recorded in 2023.
  • Year-over-year, Shares Outstanding (Diluted Average) grew 2.17% in 2022 and then skyrocketed 41.98% in 2025.
  • Sangamo Therapeutics' Shares Outstanding (Diluted Average) stood at $144.6 million in 2021, then increased by 6.76% to $154.3 million in 2022, then increased by 13.02% to $174.4 million in 2023, then grew by 15.62% to $201.7 million in 2024, then skyrocketed by 38.92% to $280.2 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $280.2 million, $304.3 million, and $257.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.